Search results
Results from the WOW.Com Content Network
QRISK3 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial ...
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [22] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries.
[33] [34] [35] Rosuvastatin 5 mg and 10 mg are examples of regimens meeting the USPSTF guideline; [32] however, insurers have discretion as to which low- and moderate-dose statin regimens to cover under this requirement, [36] and some only cover other statins. [37] The drug was billed as a "super-statin" during its clinical development; the ...
The results: 82% of patients had low risk (10% or less CHD risk at 10 years). 16% had intermediate risk (10-20%). 3% had high risk (20% or more). [23] High risk was most commonly found in patients with advanced age and was more common in men than women. [medical citation needed]
Absorption of drug is modestly decreased when taken with food however this does not reduce the clinical lipid-lowering effect. [1] The 3α-hydroxyisomeric metabolite of pravastatin is also an active HMG-CoA reductase inhibitor with approximately 2.5-10% the potency of the parent compound.
From 1996 to 2012, under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years. [ 119 ] and $13 billion a year at its peak, [ 120 ] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years."
Lovastatin and other statins have been studied for their chemopreventive and chemotherapeutic effects. No such effects were seen in the early studies. [16] More recent investigations revealed some chemopreventive and therapeutic effects, for certain types of cancer, especially in combination of statins with other anticancer drugs. [17]
As the event rate is higher in men than in women, the decrease in events is more easily seen in men than women. [163] In those at risk, but without a history of cardiovascular disease (primary prevention), statins decrease the risk of death and combined fatal and non-fatal cardiovascular disease. [164] The benefit, however, is small. [165]